Press "Enter" to skip to content

New patent for Astrazeneca drug CALQUENCE

0
Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca drug CALQUENCE

Annual Drug Patent Expirations for CALQUENCE
Annual Drug Patent Expirations for CALQUENCE

Calquence is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

Drug patent litigation for CALQUENCE.

This drug has fifty-eight patent family members in thirty-one countries.

The generic ingredient in CALQUENCE is acalabrutinib. One supplier is listed for this compound. Additional details are available on the acalabrutinib profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Astrazeneca drug CALQUENCE
    Do NOT follow this link or you will be banned from the site!